Laura Figueroa-Medrano, Carlos Ávila-Figueroa

Language: Spanish
References: 31
Page: 175-181
PDF size: 106.24 Kb.

ABSTRACT

The development and use of antiretroviral therapy in perinatal stage is one of the more important advances in prevention of vertical transmission of VIH infection; nevertheless, its use also represents a risk of adverse effects in the pregnant woman, the product or the newborn child. In the pregnant woman it has been described nausea, vomiting, gestational diabetes and preterm delivery. In the child there is risk for anemia, metabolic disorders, mitochondrial disease and neurodevelopment disorders. Some drugs such as efavirenz, have been associated to CNS malformations, therefore it is not administrated during pregnancy. At this moment, the benefits of using the accepted antiretroviral drugs are higher than the risk of adverse effects. Still, there is uncertainty about short and long term side effects of its use during perinatal stage and about the use of combined therapy in pregnant woman. This paper reviews the knowledge about the use of antiretroviral drugs in pregnant woman, fetal age and newborn child.

REFERENCES

1. Chadwick EG, Yoger R. Pediatric AIDS. Pediat Clin of North Am 1995; 42:969-92.

2. Nielsen K. Pediatric HIV infection. Clinical Management 1999.

3. Andiman WA. Medical management of the pregnant woman infected with HIV-1 and her child. Sem Perinatol 1998;22:72-86.

4. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331: 1173-80

5. Mandelbrot L, Le Chenadec J, Berrebi A, Bongain A, Benifla JL, Delfraissy JF et al. Perinatal HIV-1 transmission-interaction between zidovudine prophylaxis and mode of delivery in the French perinatal cohort. J Am Med Assoc 1998;280:55-60.

6. Thorne C, Newell ML. Epidemiology of HIV infection in the newborn. Ear Hum Develop 2000;58:1-16.

7. Kind C, Rudin C, Siegrist C-A, Wyler CA, Biedermann K, Lauper U et al. Prevention of vertical HIV transmission: additive protective effect of elective cesarean section and zidovudine prophylaxis. AIDS 1998;12:205-10.

8. Miller R. Anti-HIV therapy during pregnancy: Risk-benefit ratio. Teratology 2000; 62:288-290.

9. Minkoff H, Augernbraun M. Antiretroviral therapy for pregnant women. AM J Obstet Gynecol 1997;176:478-89.

10. Brinkman K, Hadewych JM, Burger DM, Smetink JAM, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998;12: 1735-44.

11. Centers for Disease Control and Prevention: Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 in the United States. MMWR 1998;47(R-R-2): 1-30

12. Calamandrei G, Venerosi A, Valanzano A, Alleva E. Effects of prenatal AZT+3TC treatment on open field behavior and responsiveness to scopolamine in adult mice. Pharmacol Biochem Behav 2000;67:511-7.

13. Calamandrei G, Venerosi A, Branchi I, Valanzano A, Puopolo M, Alleva E. Neurobehavioral effects of prenatal lamivudine (3TC) exposure in preweaning mice. Neurotoxicol Teratol 1999;21:365-73.

14. Calamandrei G, Venerosi A, Branchi I, Valanzano A, Puopolo M, Alleva E. Prenatal exposure to anti-HIV drugs, long-term neurobehavioral effects of lamivudine (3TC) in CD-1 mice. Neurotoxicol Teratol 2000;22:369-79.

15. Calamandrei G, Venerosi A, Branchi I, Chiarotti F, Verdina A, Bucci F et al. Effects of prenatal AZT on mouse neurobehavioral development and passive avoidance learning. Neurotoxicol Teratol 1999;21:29-40.

16. Venerosi A, Valanzano A, Alleva E. Calamandrei G. Prenatal exposure to anti-HIV drugs: neurobehavioral effects of zidovudine (AZT) + lamivudine (3TC) treatment in mice. Teratology 2001;63:23-37.

17. Mofenson LM, Fowler MG. Interruption of materno-fetal transmission. AIDS 1999;13 (Suppl A): S205-14.

18. Taylor G, Lyall H, Mercey D, Smith R, Chester T, Newell M et al. British HIV Association Guidelines for Prescribing Antiretroviral Therapy in Pregnancy (1998). 1999;75:90-97.

19. Public Health Service Task Force Recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 in the United States August 30, 2002. http//www.hivatis.org.

20. Reiff-Eldridge R, Heffner C, Ephross A, Tennis P, White A, Andrews E. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: A pharmaceutical commitment. Am J Obstetr Gynecol 2000;182.

21. Shetty A, Maldonado Y. Preventing mother to child transmission of HIV-1: An international perspective. Neo Reviews 2001;2:E75-E82.

22. Mofenson. Perinatal exposure to zidovudine-benefits and risks. N Engl J Med 2000;343: 803-805.

23. Cooper ER, Charurat M, Burns D, Blattner W, Hoff R. Trends in Antiretroviral therapy and mother-infant transmission of HIV. 1999 J Acquired Immuno Deficiency Syndromes 2000;24:45-47.

24. Lorenzi P, Spicher VM, Laubeeau B, et al. Antiretroviral therapies in pregnancy: Maternal, fetal and neonatal effects. AIDS 1998;12:F241-7.

25. Sperling RS, Shapiro DE, McSherry GD, Britto P, Cunningham BE, Culnane M. Safety of the maternal-infant zidovudine regimen utilized in the pediatric AIDS Clinical Trial Group 076 Study. AIDS 1998;12:1805-1813

26. Culnane M, Fowler MG, Lee SS et al. Late effects of in utero exposure to zidovudine among uninfected infants born to HIV-infected women. JAMA 1999; 281:151-7.

27. Eastone JA, Decker CF. New-onset diabetes mellitus associated with use of proteasa inhibitor therapy (letter). Ann Intern Med 1997;127(10):948.

28. Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999;354:1084-9

29. Lindergren M, Rhodes P, Gordon L. Fleming P. Drug safety during pregnancy and in infants. Lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance. Ann N Y Acad Sci 2000;918:222-35.

30. Bulterys M, Nesheim S, Abrams EJ, Palumbo P, Farley J et al. Lack of evidence of mitochondrial dysfunction in the offspring of HIV-infected women. Retrospective review of perinatal exposure to antiretroviral drugs in the perinatal AIDS collaborative transmission study. Ann N Y Acad Sci 2000;918:212-21.

31. French Perinatal Cohort Study Group. Risk of early febrile seizure with perinatal exposure to nucleoside analogues. Lancet 2002;359: 583-4.